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1. BACKGROUND {#cac212004-sec-0050}
=============

Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southeastern Asia, especially Guangdong province in South China. Approximately 86,700 incident cases of NPC and 50,800 deaths have been reported in 2012 \[[1](#cac212004-bib-0001){ref-type="ref"}\] Radiotherapy is the primary treatment of NPC because of its radiosensitive feature and deep anatomic location \[[2](#cac212004-bib-0002){ref-type="ref"}, [3](#cac212004-bib-0003){ref-type="ref"}\]. For locally advanced NPC, concurrent chemoradiotherapy (CCRT) has been established as the standard treatment protocol according to findings from clinical trials \[[4](#cac212004-bib-0004){ref-type="ref"}, [5](#cac212004-bib-0005){ref-type="ref"}, [6](#cac212004-bib-0006){ref-type="ref"}\].

With the development of radiotherapy, the survival rates of NPC patients have increased due to better locoregional control \[[7](#cac212004-bib-0007){ref-type="ref"}, [8](#cac212004-bib-0008){ref-type="ref"}\]. Besides, induction therapy with gemcitabine and cisplatin was also verified to be more effective than standard CCRT \[[9](#cac212004-bib-0009){ref-type="ref"}\]. Unfortunately, approximately 6%‐15% of NPC patients develop metastatic lesions at the time of initial diagnosis without any prior treatment, and the common metastatic sites tend to be the bones, lungs, and liver \[[3](#cac212004-bib-0003){ref-type="ref"}, [10](#cac212004-bib-0010){ref-type="ref"}, [11](#cac212004-bib-0011){ref-type="ref"}\]. Once distant lesions have been detected, platinum‐based combination therapy is considered the standard treatment and has achieved satisfactory response rates \[[12](#cac212004-bib-0012){ref-type="ref"}, [13](#cac212004-bib-0013){ref-type="ref"}, [14](#cac212004-bib-0014){ref-type="ref"}, [15](#cac212004-bib-0015){ref-type="ref"}\]. Furthermore, Chen et al. \[[16](#cac212004-bib-0016){ref-type="ref"}\] have evaluated the impact of different treatment strategies on patients' survival and confirmed the treatment value of locoregional radiotherapy (LRRT) following palliative chemotherapy (PCT) in patients with distant lesions at initial diagnosis.

Capecitabine is an oral fluoropyrimidine which has previously been used as a second‐line or salvage therapy in patients with metastatic NPC \[[17](#cac212004-bib-0017){ref-type="ref"}, [18](#cac212004-bib-0018){ref-type="ref"}\]. According to a phase II trial, capecitabine plus cisplatin was an active first‐line combination in metastatic NPC and only required a short hospital stay with a response rate of 54% \[[19](#cac212004-bib-0019){ref-type="ref"}\]. In other malignancies such as metastatic colorectal cancer, capecitabine maintenance therapy has been considered an appropriate option following induction chemotherapy based on the results of a randomized clinical trial \[[20](#cac212004-bib-0020){ref-type="ref"}\]. However, research on *de‐novo* metastatic NPC patients receiving PCT and LRRT with or without capecitabine maintenance therapy has been poorly documented. The potential treatment efficacy of capecitabine prompted us to design this retrospective study and explore whether the application of capecitabine after LRRT could prolong the overall survival (OS) of these patients.

2. PATIENTS AND METHODS {#cac212004-sec-0060}
=======================

2.1. Patient selection {#cac212004-sec-0070}
----------------------

Patients with newly diagnosed *de novo* metastatic NPCs treated at the Sun Yat‐sen University Cancer Center (SYSUCC) between July 1, 2006 and December 31, 2016 were selected. The eligibility criteria were as follows: (1) with histology‐confirmed NPC; (2) had distant metastasis at diagnosis; (3) age ≥ 18 years; (4) had complete treatment information; (5) received platinum‐based PCT; (6) received at least 3 cycles of capecitabine in the maintenance group; (7) received LRRT; (8) Karnofsky performance score (KPS) \>70; (9) no previous malignancy; (10) normal renal (creatinine clearance ≥60 mL/min) and liver functions (alanine aminotransferase ≤ 2 times the upper limit of normal); (11) had pretreatment Epstein‐Barr virus (EBV) DNA serology results. The flow chart of patient inclusion is shown in Figure [1](#cac212004-fig-0001){ref-type="fig"}. All patients were restaged according to the 8th edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) TNM staging system. Before treatment, each patient was assessed by routine inspection and received physical examination, fiber optic nasopharyngoscopy, magnetic resonance imaging (MRI) or computed tomography (CT) of the head and neck, chest radiography or CT, abdominal sonography or CT, bone scan, and hematologic examination. Positron emission tomography/computed tomography (PET/CT) was also applied selectively. This study was approved by the Research Ethics Committee of SYSUCC.

![Flow chart of patient inclusion. NPC, nasopharyngeal carcinoma; EBV, Epstein‐Barr virus](CAC2-40-32-g001){#cac212004-fig-0001}

2.2. Chemotherapy, radiotherapy, and capecitabine maintenance therapy {#cac212004-sec-0080}
---------------------------------------------------------------------

The common PCT regimens included TPF \[intravenous administration of docetaxel (60 mg/m^2^) on day 1 and cisplatin (20‐25 mg/m^2^) on days 1‐3 plus 120‐hour continuous intravenous infusion of 5‐fluorouracil (0.5‐0.8 g/m^2^) on days 1‐5\], PF \[intravenous administration of cisplatin (20‐30 mg/m^2^) on days 1‐3 plus 120‐hour continuous intravenous infusion of 5‐fluorouracil (0.8‐1.0 g/m^2^) on days 1‐5\], GP \[intravenous administration of cisplatin (20‐30 mg/m^2^) on days 1‐3 and gemcitabine (0.8‐1.0 g/m^2^) on days 1 and 8\], and TP \[intravenous administration of docetaxel (75 mg/m^2^) on day 1 and cisplatin (20‐25 mg/m^2^) on days 1‐3\]. All regimens were repeated every 3 weeks. All patients were treated with intensity‐modulated radiotherapy (IMRT) after PCT. The total dose of radiotherapy was 68‐70 Gy (1.8‐2.3 Gy/fraction, five daily fractions per week) for the primary tumor. IMRT was designed according to previous studies \[[7](#cac212004-bib-0007){ref-type="ref"}, [21](#cac212004-bib-0021){ref-type="ref"}\]. Patients received oral administration of capecitabine (1.0 g/m^2^) twice daily on days 1‐14, every 3 weeks.

2.3. Quantification of plasma EBV DNA levels {#cac212004-sec-0090}
--------------------------------------------

EBV DNA has been demonstrated to be an important biomarker for NPC \[[22](#cac212004-bib-0022){ref-type="ref"}, [23](#cac212004-bib-0023){ref-type="ref"}, [24](#cac212004-bib-0024){ref-type="ref"}\], and we used the level of EBV DNA to stratify risk in these patients. Pretreatment EBV DNA levels were measured with real‐time quantitative polymerase chain reaction (qPCR) as described in a previous study \[[25](#cac212004-bib-0025){ref-type="ref"}\]. Receiver operating characteristic (ROC) curve analysis was used to establish the cut‐off value.

2.4. Outcome measurement and follow‐up {#cac212004-sec-0100}
--------------------------------------

OS was the primary endpoint in this study, which was defined as the time from diagnosis to death of any cause or censored at the date of last follow‐up. Progression‐free survival (PFS) was the secondary endpoint, which was defined as the time from diagnosis to disease progression or death of any cause or censored at the date of last follow‐up. After treatment completion, patients were assessed every 3 months during the next 3 years and every 6 months thereafter until death. Fiber optic nasopharyngoscopy, MRI or CT of the head and neck, chest scan (radiography or CT), and abdominal scan (sonography or CT) were performed routinely or upon clinical indication of tumor progression. PET/CT was applied if clinically indicated. The last follow‐up date was January 15, 2019.

2.5. Statistical analysis {#cac212004-sec-0110}
-------------------------

The propensity score matching (PSM) method was used to eliminate potential confounders that may influence treatment effects between patients treated with capecitabine and those who were not after PCT and IMRT. Propensity scores were calculated using logistic regression with a ratio of 1:3 to balance the covariates of gender, age, T stage, N stage, metastatic sites, and pretreatment EBV DNA levels. The Chi‐square test or Fisher\'s exact test was used to assess the differences between the two groups. We plotted the survival curves using the Kaplan‐Meier method and compared survival differences using the log‐rank test. Univariate and multivariate analyses using the Cox proportional hazard model was performed with the following variables: gender, age, T stage, N stage, metastatic site, pretreatment EBV DNA level, and maintenance therapy. All variables were included into the multivariate Cox model. Interaction analysis was performed between maintenance therapy and pretreatment EBV DNA level. The interaction analysis was conducted by means of a test of treatment‐by‐covariate interaction on the basis of the Cox proportional hazards model \[[26](#cac212004-bib-0026){ref-type="ref"}\]. Adverse events (AEs) were evaluated according to Common Terminology Criteria for Adverse Events (version 4.0). Analyses were performed using the Statistical Package for Social Sciences, version 24.0 (IBM Corporation, Armonk, NY, USA) and R program (<http://www.R-project.org>). All statistical tests were two‐sided, and *P* \< 0.05 was considered statistically significant.

3. RESULTS {#cac212004-sec-0120}
==========

3.1. Clinical characteristics and OS {#cac212004-sec-0130}
------------------------------------

Between July 1, 2006 and December 31, 2016, 298 *de novo* NPC patients were found eligible. The median age of all patients was 46 years (range, 18‐70 years); 248 (83.2%) were male, and 64 (21.5%) received capecitabine maintenance therapy. The median duration of PCT was 5 cycles (range, 2‐10 cycles) in the original cohort. Between PCT and IMRT, the median interval was 21 days (range, 10‐38 days). The median duration of capecitabine maintenance therapy was 6 cycles (range, 3‐18 cycles). The median interval between IMRT and capecitabine maintenance therapy was 30 days (range, 19‐45 days). After matching with the 64 patients in the maintenance group at a 1:3 ratio, 192 patients who did not receive capecitabine maintenance therapy were identified and classified into the non‐maintenance group. Table [1](#cac212004-tbl-0001){ref-type="table"} includes the other salient characteristics. In terms of PCT cycles, concurrent chemotherapy, and radiotherapy, there were no significant differences between maintenance group and non‐maintenance group (Table S1). In the original cohort, the median follow‐up time was 33.1 months \[interquartile range, 19.9‐53.4 months\]. During follow‐up, 138 (46.3%) patients died. The 1‐, 3‐, and 5‐year OS rates were 91.4%, 63.3%, and 46.7%, respectively. The OS and PFS curves of the original cohort are shown in Figure S1.

###### 

Clinical characteristics of patients with *de novo* metastatic nasopharyngeal carcinoma in the capecitabine maintenance and non‐maintenance groups in the original cohort and the matched cohort

                                                          The original cohort \[cases (%)\]               The matched cohort \[cases (%)\]                            
  ------------------------------------------------------- ----------------------------------- ----------- ---------------------------------- ------------ ----------- -------
  Total                                                   234                                 64                                             192          64          
  Gender                                                                                                                                                              
  Male                                                    198 (84.6)                          50 (78.1)   0.257                              113 (81.3)   50 (78.1)   0.716
  Female                                                  36 (15.4)                           14 (21.9)                                      79 (18.8)    14 (21.9)   
  Age (years)                                                                                                                                                         
  ≤46                                                     114 (48.7)                          40 (62.5)   0.066                              113 (58.9)   40 (62.4)   0.660
  \>46                                                    120 (51.3)                          24 (37.5)                                      79 (41.1)    24 (37.5)   
  T stage[\#](#cac212004-tbl1-note-0002){ref-type="fn"}                                                                                                               
  T1                                                      9 (3.8)                             2 (3.1)     0.473                              9 (4.7)      2 (3.1)     0.493
  T2                                                      30 (12.8)                           13 (20.3)                                      29 (15.1)    13 (20.3)   
  T3                                                      118 (50.3)                          28 (43.8)                                      102 (53.1)   28 (43.8)   
  T4                                                      77 (32.9)                           21 (32.8)                                      52 (27.1)    21 (32.8)   
  N stage[\#](#cac212004-tbl1-note-0002){ref-type="fn"}                                                                                                               
  N0                                                      9 (3.8)                             3 (4.7)     0.333                              8 (4.2)      3 (4.7)     0.730
  N1                                                      43 (18.4)                           10 (15.6)                                      39 (20.3)    10 (15.6)   
  N2                                                      89 (38.0)                           32 (50.0)                                      82 (42.7)    32 (50.0)   
  N3                                                      93 (39.7)                           19 (29.7)                                      63 (32.8)    19 (29.7)   
  Metastatic sites                                                                                                                                                    
  Bones                                                   122 (52.1)                          37 (57.8)   0.657                              105 (54.7)   37 (57.8)   0.574
  Lungs                                                   32 (13.7)                           5 (7.8)                                        28 (14.6)    5 (7.8)     
  Liver                                                   17 (7.3)                            6 (9.4)                                        14 (7.3)     6 (9.4)     
  Distant nodes                                           22 (9.4)                            7 (10.9)                                       14 (7.3)     7 (9.7)     
  Multiple sites                                          41 (17.5)                           9 (14.1)                                       31 (16.1)    9 (17.7)    
  Pretreatment EBV DNA (copies/mL)                                                                                                                                    
  ≤30,000                                                 123 (52.6)                          31 (48.4)   0.575                              99 (51.6)    31 (48.4)   0.773
  ˃30,000                                                 111 (47.4)                          33 (51.6)                                      93 (48.4)    33 (51.6)   

Abbreviations: EBV = Epstein‐Barr virus

According to the 8th edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) TNM staging system

P values were calculated using the Pearson χ^2^ test

John Wiley & Sons, Ltd.

3.2. Cut‐off value of pretreatment EBV DNA levels {#cac212004-sec-0140}
-------------------------------------------------

The median pretreatment EBV DNA level for the 298 patients was 24,500 (range, 0‐58,600,000) copies/mL. According to the ROC curve analysis, the cut‐off value was 29,350 copies/mL applied to discriminate OS curves of the two groups (sensitivity = 0.594, specificity = 0.604, area under curve \[AUC\] = 0.613) (Figure [2](#cac212004-fig-0002){ref-type="fig"}). To optimize the cut‐off value for its potential acceptance and clinical application, we rounded to the nearest integer of 30,000 copies/mL.

![Receiver operating characteristic (ROC) curve analysis used to determine the cut‐off value of pretreatment EBV DNA levels to discriminate OS curves of the two groups. AUC, area under curve](CAC2-40-32-g002){#cac212004-fig-0002}

3.3. Relationship between pre‐ and posttreatment EBV DNA levels {#cac212004-sec-0150}
---------------------------------------------------------------

After treatment, a total of 262 patients had the data of posttreatment EBV DNA levels. In details, EBV DNA could not be detected (0 copy/mL) in 164 patients, whereas 98 patients had detectable EBV DNA. We further explored the relationship between pretreatment and posttreatment EBV DNA levels. As shown in Table S2, a high pretreatment EBV DNA level (\>30,000 copies/mL) was significantly associated with a detectable EBV DNA level after treatment (\>0 copies/mL) (*P* = 0.001).

3.4. Survival analysis based on the treatment strategies {#cac212004-sec-0160}
--------------------------------------------------------

We compared patients' survival between the capecitabine maintenance and non‐maintenance groups in the matched cohort. In the univariate analysis, we found that the application of capecitabine maintenance therapy contributed to survival prolongation. The 3‐year OS rate was higher in the capecitabine maintenance group than in the non‐maintenance group (68.5% vs. 61.8%, *P* = 0.037) (Figure [3](#cac212004-fig-0003){ref-type="fig"}). Notably, there was no significant difference in OS between patients receiving different chemotherapy regimens, and there was no significant interaction effect between maintenance therapy and chemotherapy (all *P* \> 0.05) (data not shown). We performed multivariate analyses in the matched cohort and found that the risk of death between the two groups was similar (hazard ratio \[HR\], 0.632; 95% confidence interval \[CI\], 0.399‐1.000; *P* = 0.050) (Table [2](#cac212004-tbl-0002){ref-type="table"}). More than one metastatic site was an independent risk factor of OS (HR, 2.736; 95% CI, 1.712‐4.372, *P* \< 0.001). Additionally, patients with higher EBV DNA levels experienced worse survival outcome (HR, 1.451; 95% CI, 1.026‐2.051, *P* = 0.035).

![Kaplan‐Meier overall survival curves of patients with *de novo* metastatic nasopharyngeal carcinoma receiving capecitabine maintenance therapy or not in the matched cohort. HR, hazard ratio; CI, confidence interval](CAC2-40-32-g003){#cac212004-fig-0003}

###### 

Univariate and multivariate analyses for prognostic factors of OS of patients with *de novo* metastatic nasopharyngeal carcinoma receiving capecitabine maintenance therapy or not in the matched cohort

                               Univariate analysis                 Multivariate analysis                             
  ---------------------------- --------------------- ------------- ----------------------- ----------- ------------- ---------
  Gender                                                                                                             
  Male                         Reference                                                   Reference                 
  Female                       0.679                 0.415‐1.109   0.122                   0.666       0.404‐1.098   0.111
  Age                                                                                                                
  ≤46 years                    Reference                                                   Reference                 
  \>46 years                   0.982                 0.683‐1.411   0.922                   1.029       0.708‐1.495   0.881
  T stage                                                                                                            
  T1‐2                         Reference                                                   Reference                 
  T3‐4                         0.995                 0.644‐1.536   0.980                   0.797       0.507‐1.252   0.325
  N stage                                                                                                            
  N0‐1                         Reference                                                   Reference                 
  N2‐3                         1.213                 0.789‐1.865   0.379                   1.162       0.749‐1.803   0.503
  Metastatic site                                                                                                    
  Bones                        Reference                                                   Reference                 
  Lungs                        0.954                 0.538‐1.659   0.843                   1.023       0.577‐1.813   0.938
  Liver                        1.157                 0.576‐2.326   0.682                   1.189       0.588‐2.408   0.630
  Distant nodes                0.494                 0.179‐1.358   0.171                   0.626       0.224‐1.750   0.372
  Multiple                     2.746                 1.735‐4.347   \<0.001                 2.736       1.712‐4.372   \<0.001
  Pretreatment EBV DNA level                                                                                         
  ≤30,000 copies/mL            Reference                                                   Reference                 
  ˃30,000 copies/mL            1.851                 1.259‐2.616   0.001                   1.614       1.106‐2.353   0.013
  Treatment strategy                                                                                                 
  Non‐maintenance              Reference                                                   Reference                 
  Maintenance                  0.618                 0.392‐0.975   0.039                   0.632       0.399‐1.000   0.050

Abbreviations: HR = hazard ratio; CI = confidence interval; EBV = Epstein‐Barr virus.

John Wiley & Sons, Ltd.

3.5. Subgroup analysis in the matched cohort {#cac212004-sec-0170}
--------------------------------------------

We further detected whether there was interaction effect between maintenance therapy and EBV DNA levels. After adjusting for gender, age, T stage, N stage, and metastatic site, we found that the curative effect of capecitabine was different in patients with different pretreatment EBV DNA levels (*P* = 0.035) (Table S3). Thus, we investigated the role of capecitabine maintenance therapy in patients with different EBV DNA levels. Among patients with EBV DNA ≤30,000 copies/mL, the 3‐year OS rate of the non‐maintenance group was significantly lower than that of the maintenance group (68.1% vs. 90.0%, *P* = 0.003). However, among patients with EBV DNA \>30,000 copies/mL, the 3‐year OS rate was comparable in these two groups (54.8% vs. 45.8%, *P* = 0.835) (Figure [4](#cac212004-fig-0004){ref-type="fig"}). In multivariate analysis, maintenance therapy was identified as a protective factor for patients with low EBV DNA levels (HR, 0.277; 95% CI, 0.107--0.722; *P* = 0.009), but not for patients with high EBV DNA levels (HR, 0.896; 95% CI, 0.520--1.545; *P* = 0.693) (Table [3](#cac212004-tbl-0003){ref-type="table"}). We further analyzed the association of capecitabine maintenance therapy with survival in patients with different statuses of posttreatment EBV DNA (detectable and undetectable). Among the 262 patients who had the data of posttreatment EBV DNA levels, we found that only patients with undetectable post‐treatment EBV DNA could benefit from capecitabine maintenance therapy (*P* = 0.008), whereas patients with detectable posttreatment EBV DNA could not (*P* = 0.484) (Figure S2).

![Kaplan‐Meier overall survival curves of *de novo* metastatic nasopharyngeal carcinoma patients with different pretreatment EBV DNA levels in the non‐maintenance and maintenance groups in the matched cohort. (A) Low‐risk subgroup with pretreatment EBV DNA ≤30,000 copies/mL. (B) High‐risk subgroup with pretreatment EBV DNA \>30,000 copies/mL. *P* values were calculated using the log‐rank test. EBV, Epstein‐Barr virus](CAC2-40-32-g004){#cac212004-fig-0004}

###### 

Cox proportional multivariate analysis for prognostic factors of OS of *de novo* metastatic nasopharyngeal carcinoma patients with different pretreatment EBV DNA levels in the matched cohort

                       Low EBV DNA level                 High EBV DNA level                              
  -------------------- ------------------- ------------- -------------------- ----------- -------------- -------
  Gender                                                                                                 
  Male                 Reference                                              Reference                  
  Female               0.517               0.229‐1.168   0.113                0.779       0.407‐1.492    0.452
  Age                                                                                                    
  ≤46 years            Reference                                              Reference                  
  \>46 years           1.128               0.604‐2.104   0.706                0.942       0.578‐1.535    0.810
  T stage                                                                                                
  T1‐2                 Reference                                              Reference                  
  T3‐4                 0.846               0.403‐1.776   0.658                0.731       0.399‐1.338    0.309
  N stage                                                                                                
  N0‐1                 Reference                                              Reference                  
  N2‐3                 1.863               0.904‐3.840   0.092                0.899       0.506‐1.597    0.717
  Metastatic site                                                                                        
  Bones                Reference                                              Reference                  
  Lungs                1.188               0.539‐2.620   0.669                0.876       0.369‐2.083    0.765
  Liver                1.194               0.349‐4.086   0.777                1.265       0.527‐3.035    0.599
  Distant nodes        0.667               0.153‐2.920   0.591                0.756       0.176‐3.251    0.707
  Multiple             4.124               1.867‐9.109   \<0.001              2.180       1.188‐4.002    0.012
  Treatment strategy                                                                                     
  Non‐maintenance      Reference                                              Reference                  
  Maintenance          0.277               0.107‐0.722   0.009                0.896       0.520--1.545   0.693

Abbreviations: EBV = Epstein‐Barr virus; HR = hazard ratio; CI = confidence interval.

The cutoff of EBV DNA was 30,000 copies/mL.

John Wiley & Sons, Ltd.

3.6. Adverse events {#cac212004-sec-0180}
-------------------

The treatment‐related adverse events (AEs) of each group were also analyzed. A total of 37 treatment‐related grade 3‐4 AEs were reported in the maintenance group and 44 in the non‐maintenance group. As shown in Table S4, leukocytopenia, neutropenia, and hand‐foot syndrome were more common in the maintenance group (all *P* \< 0.05). No toxicity‐associated deaths were observed.

4. DISCUSSION {#cac212004-sec-0190}
=============

Our results showed that the application of capecitabine after PCT and LRRT significantly prolonged the survival of patients with *de novo* metastatic nasopharyngeal carcinoma. Subgroup analysis further demonstrated that only patients with low EBV DNA levels (≤30,000 copies/mL) could benefit from capecitabine maintenance therapy, whereas patients with high EBV DNA levels (\>30,000 copies/mL) could not benefit.

Capecitabine is an oral fluoropyrimidine with single‐agent activity. Several previous clinical trials have explored the efficacy and safety of capecitabine in metastatic NPC \[[17](#cac212004-bib-0017){ref-type="ref"}, [19](#cac212004-bib-0019){ref-type="ref"}, [27](#cac212004-bib-0027){ref-type="ref"}, [28](#cac212004-bib-0028){ref-type="ref"}, [29](#cac212004-bib-0029){ref-type="ref"}\]. A phase II study in Chinese patients showed that the combination of capecitabine and cisplatin was effective and well‐tolerated as a first‐line treatment among metastatic NPC patients \[[27](#cac212004-bib-0027){ref-type="ref"}\]. Similarly, Chua et al. \[[19](#cac212004-bib-0019){ref-type="ref"}\] conducted a multicenter phase II study involving 39 patients with metastatic NPC and reported that the overall response rate was 53.8% and the median OS was 28.0 months. However, due to the limitation of the small sample size, it was difficult to get the exact conclusion on whether capecitabine could further prolong the survival of patients with metastatic NPC. Besides, patients with either distant metastases at diagnosis or relapse after primary treatment were all involved in these studies, which increased the heterogeneity of patients. In the present study, all the patients were confirmed to have metastasis before treatment. Based on a relatively large sample size, we could explore the curative effect of capecitabine as maintenance therapy for *de novo* metastatic NPC.

Used as a maintenance therapy regimen, capecitabine also showed treatment effects on other metastatic malignancies \[[20](#cac212004-bib-0020){ref-type="ref"}, [30](#cac212004-bib-0030){ref-type="ref"}, [31](#cac212004-bib-0031){ref-type="ref"}\]. According to a randomized, open‐labeled, multicenter phase III trial, the application of capecitabine maintenance therapy significantly prolonged the survival of metastatic colorectal cancer patients and was considered to have acceptable toxicities \[[20](#cac212004-bib-0020){ref-type="ref"}\]. The median OS was 25.63 months in the maintenance group and 23.30 months in the non‐maintenance group. Neutropenia, hand‐foot syndrome, and mucositis were the most common grade 3‐4 AEs. Another study assessing breast cancer indicated that maintenance with single‐agent capecitabine therapy was an effective and well‐tolerated treatment option for HER2‐negative metastatic breast cancer patients whose disease was controlled after 6 cycles of docetaxel plus capecitabine chemotherapy \[[31](#cac212004-bib-0031){ref-type="ref"}\]. In the present study, the OS rate was higher in the maintenance group than in the non‐maintenance group. Multivariate analysis also showed that capecitabine maintenance therapy was an independent prognostic factor. Our results were consistent with the results of other metastatic malignancies, verifying that capecitabine maintenance therapy could also prolong the survival of metastatic NPC patients. Besides, the rates of AEs in the present study were similar to previous findings, and most AEs were mild and manageable, suggesting that the application of capecitabine was safe. Although some grade 3‐4 AEs (such as leukocytopenia and hand‐foot syndrome) were more common in the maintenance group than in the non‐maintenance group, the rate was still low. Notably, there were no toxicity‐associated deaths in the present study.

We further performed a subgroup analysis based on different EBV DNA levels. Interestingly, we noted that only patients with low pretreatment EBV DNA levels (≤30,000 copies/mL) benefited from capecitabine maintenance, whereas patients with high EBV DNA levels did not. This result might be explained by that plasma EBV DNA level was correlated with the tumor burden and prognosis of NPC \[[22](#cac212004-bib-0022){ref-type="ref"}, [23](#cac212004-bib-0023){ref-type="ref"}, [32](#cac212004-bib-0032){ref-type="ref"}, [33](#cac212004-bib-0033){ref-type="ref"}, [34](#cac212004-bib-0034){ref-type="ref"}, [35](#cac212004-bib-0035){ref-type="ref"}\]. For patients with a low EBV DNA level, the distant lesions and primary tumor were better controlled after PCT and LRRT compared with patients with high EBV DNA level. The relationship between pre‐ and posttreatment EBV DNA levels also verified this point. Patients with low pretreatment EBV DNA levels were inclined to have undetectable EBV DNA levels after treatment and showed better disease control. Thus, capectabline maintenance therapy could help these patients achieve long‐term survival. However, patients with high EBV DNA levels experienced a more profound tumor burden and serious conditions. Their distant lesions were more difficult to eliminate compared with patients with low EBV DNA levels. Thus, the post‐LRRT capecitabine might be insufficient in inhibiting tumor progression. Intensive therapy such as the administration of targeted drugs or immunotherapy might be helpful in treating such patients \[[36](#cac212004-bib-0036){ref-type="ref"}, [37](#cac212004-bib-0037){ref-type="ref"}, [38](#cac212004-bib-0038){ref-type="ref"}\].

Distant metastasis is the major cause of death in NPC patients, and platinum‐based PCT was established as the standard treatment. Previous study also demonstrated that LRRT could also benefit these patients in achieving longer OS compared with PCT alone. The present study put forward another view that capecitabine maintenance therapy following LRRT further prolonged the survival of *de novo* metastatic NPC patients with the safety profile and should be applied based on the disease condition. EBV DNA, which was the most important biomarker in NPC, could be used to select suitable patients for the therapy. Besides, capecitabine has the advantages of convenient administration. Therefore, patients do not need to stay in hospital in the duration of maintenance therapy. Because of the low rate of capecitabine‐related AEs, it was not strict in toxicity monitoring \[[20](#cac212004-bib-0020){ref-type="ref"}\]. The monitoring hematologic examination can be easily conduced in local hospitals. Therefore, the use of capecitabine does not affect the qualities of patients' life obviously. Considered as an appropriate option for metastatic NPC patients, maintenance therapy with oral capecitabine might play an important role in the management of metastatic NPC in future.

There are several limitations to this study. First, this was a retrospective study and selective bias was unavoidable. Therefore, the PSM method and multivariate analysis were applied to minimize the bias. Besides, capecitabine‐related AEs were hard to record accurately due to the retrospective design. Second, only 298 patients were eligible in the study duo to the low incidence of *de novo* metastatic NPC. Third, all patients were from one treatment center in an endemic area. Therefore, a multi‐institutional prospective study is required to validate our results in the future.

5. CONCLUSIONS {#cac212004-sec-0200}
==============

Pretreatment EBV DNA level is associated with the prognosis of *de novo* metastatic NPC. Capecitabine maintenance therapy can significantly prolong the OS of *de novo* metastatic NPC patients with pretreatment EBV DNA ≤ 30,000copies/mL.
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